Search for publications

Search results

706 items matching your search terms.

A model of culturally-informed integrated diabetes education and eye screening in indigenous primary care services and specialist diabetes clinics: Study protocol

Atkinson-Briggs, S. Jenkins, A. Keech, A. Ryan, C. Brazionis, L. Centre of Research Excellence in Diabetic Retinopathy Study, Group
JOURNAL OF ADVANCED NURSING, 2021     DOI:10.1111/jan.14734

Genetic risk score to identify risk of venous thromboembolism in patients with cardiometabolic disease

Marston, N. A. Melloni, G. E. M. Gurmu, Y. Bonaca, M. P. Kamanu, F. K. Roselli, C. Lee, C. Cavallari, I. Giugliano, R. P. Scirica, B. M. Bhatt, D. L. Steg, P. G. Cohen, M. Storey, R. F. Keech, A. C. Raz, I. Mosenzon, O. Braunwald, E. Lubitz, S. A. Ellinor, P. T. Sabatine, M. S. Ruff, C. T.
CIRC GENOM PRECIS MED, 2021     DOI:10.1161/CIRCGEN.120.003006

Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial

Wittert, G. Bracken, K. Robledo, K. P. Grossmann, M. Yeap, B. B. Handelsman, D. J. Stuckey, B. Conway, A. Inder, W. McLachlan, R. Allan, C. Jesudason, D. Fui, M. N. T. Hague, W. Jenkins, A. Daniel, M. Gebski, V. Keech, A.
LANCET DIABETES ENDOCRINOL, 2021     DOI:10.1016/S2213-8587(20)30367-3

A microRNA signature in acute coronary syndrome patients and modulation by colchicine

Barraclough, J. Y. Joglekar, M. V. Januszewski, A. S. Martinez, G. Celermajer, D. S. Keech, A. C. Hardikar, A. A. Patel, S.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2020     DOI:10.1177/1074248420922793

Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study

Cao, J. Y. Waldman, B. O'Connell, R. Sullivan, D. R. Scott, R. S. Aryal, N. Gebski, V. Marschner, I. Taskinen, M. R. Simes, J. R. McGill, N. Jenkins, A. J. Keech, A. C. Field investigators
DIABETES, OBESITY AND METABOLISM, 2020     DOI:10.1111/dom.14046

Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: Secondary analysis from the FOURIER randomized clinical trial

Deedwania, P. Murphy, S. A. Scheen, A. Badariene, J. Pineda, A. L. Honarpour, N. Keech, A. C. Sever, P. S. Pedersen, T. R. Sabatine, M. S. Giugliano, R. P.
JAMA CARDIOL, 2020     DOI:10.1001/jamacardio.2020.3151

Questioning statin therapy for older patients - Authors' reply

Fulcher, J. Keech, A. Simes, J. Baigent, C. Collins, R.
LANCET, 2020     DOI:10.1016/S0140-6736(19)33159-9

Cognition after lowering LDL-cholesterol with evolocumab

Gencer, B. Mach, F. Guo, J. Im, K. Ruzza, A. Wang, H. Kurtz, C. E. Pedersen, T. R. Keech, A. C. Ott, B. R. Sabatine, M. S. Giugliano, R. P. Fourier Investigators
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020     DOI:10.1016/j.jacc.2020.03.039

Efficacy of evolocumab on cardiovascular outcomes in patients with recent myocardial infarction: A prespecified secondary analysis from the FOURIER trial

Gencer, B. Mach, F. Murphy, S. A. De Ferrari, G. M. Huber, K. Lewis, B. S. Ferreira, J. Kurtz, C. E. Wang, H. Honarpour, N. Keech, A. C. Sever, P. S. Pedersen, T. R. Sabatine, M. S. Giugliano, R. P.
JAMA CARDIOL, 2020     DOI:10.1001/jamacardio.2020.0882

Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials

Gencer, B. Marston, N. A. Im, K. Cannon, C. P. Sever, P. Keech, A. Braunwald, E. Giugliano, R. P. Sabatine, M. S.
LANCET, 2020     DOI:10.1016/S0140-6736(20)32332-1

Stroke prevention with the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis

Giugliano, R. P. Pedersen, T. R. Saver, J. L. Sever, P. S. Keech, A. C. Bohula, E. A. Murphy, S. A. Wasserman, S. M. Honarpour, N. Wang, H. Lira Pineda, A. Sabatine, M. S. Fourier Investigators
STROKE, 2020     DOI:10.1161/STROKEAHA.119.027759

FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease

Januszewski, A. S. Watson, C. J. O'Neill, V. McDonald, K. Ledwidge, M. Robson, T. Jenkins, A. J. Keech, A. C. McClements, L.
SCI REP, 2020     DOI:10.1038/s41598-020-78676-6

Rare case of infiltrative cardiomyopathy secondary to scleromyxoedema

Khandkar, C. Vaidya, K. Penglase, R. Cai, K. Shin, J. S. Hunyor, I. Keech, A. McGill, N.
INTERNAL MEDICINE JOURNAL, 2020     DOI:10.1111/imj.14695

Predicting benefit from evolocumab therapy in patients with atherosclerotic disease using a genetic risk score: Results from the FOURIER trial

Marston, N. A. Kamanu, F. K. Nordio, F. Gurmu, Y. Roselli, C. Sever, P. S. Pedersen, T. R. Keech, A. C. Wang, H. Lira Pineda, A. Giugliano, R. P. Lubitz, S. A. Ellinor, P. T. Sabatine, M. S. Ruff, C. T.
CIRCULATION, 2020     DOI:10.1161/CIRCULATIONAHA.119.043805

The effect of PCSK9 inhibition on the risk of venous thromboembolism

Marston, N. A. Gurmu, Y. Melloni, G. E. M. Bonaca, M. Gencer, B. Sever, P. S. Pedersen, T. R. Keech, A. C. Roselli, C. Lubitz, S. A. Ellinor, P. T. O'Donoghue, M. L. Giugliano, R. P. Ruff, C. T. Sabatine, M. S.
CIRCULATION, 2020     DOI:10.1161/CIRCULATIONAHA.120.046397